Lab
Corona Pathology CPS INC.
Corona Pathology CPS INC. was paid $411K by Medicaid between Jan 2018 and Aug 2022, across 56 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 32% of everything it billed.
33Billing provider infoCORONA PATHOLOGY CPS INC.
BURBANK, CA 91505
BURBANK, CA 91505
33aNPI1073949327assigned 09/18/2013
33bProvider typeClinical Medical Laboratory
28Total paid$411K
24GClaims80,318
24DCodes billed56
24AFirst – last monthJan 2018 – Aug 2022
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#242 of 561
Median peer was paid$222K
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,075 | $34K | |
| 2019 | 10,032 | $43K | |
| 2020 | 13,513 | $85K | |
| 2021 | 8,571 | $97K | |
| 2022 | 6,127 | $152K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 32% | 6,307 | 5,585 | $130K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 19% | 7,389 | 7,216 | $78K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.4% | 1,202 | 1,104 | $26K |
| 87150 | 5.7% | 1,506 | 1,448 | $23K | |
| 87631 | 5.5% | 1,242 | 1,163 | $23K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.0% | 3,074 | 2,802 | $12K |
| 87481 | 2.6% | 2,281 | 2,147 | $11K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.5% | 567 | 563 | $10K |
| 87486 | 2.5% | 4,131 | 3,786 | $10K | |
| 87529 | 2.3% | 563 | 559 | $9K | |
| 87634 | 1.9% | 567 | 561 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 587 | 577 | $7K |
44 more codes
| 87581 | 1.7% | 4,137 | $7K | |
| 87541 | 1.4% | 1,010 | $6K | |
| 87640 | 1.3% | 1,027 | $5K | |
| 87652 | 1.2% | 2,088 | $5K | |
| 80299 | 1.2% | 7,018 | $5K | |
| 87641 | 1.1% | 2,081 | $5K | |
| 82945 | 1.1% | 2,670 | $5K | |
| 87500 | 1.1% | 2,148 | $4K | |
| 87498 | <1% | 895 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 690 | $4K |
| 87507 | <1% | 367 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 382 | $2K |
| 82436 | <1% | 4,834 | $2K | |
| 82043 | <1% | 4,893 | $2K | |
| 84300 | <1% | 4,837 | $2K | |
| 84133 | <1% | 4,840 | $1K | |
| 0099U | <1% | 606 | $660.00 | |
| 86003 | <1% | 1,510 | $502.20 | |
| 80053 | Comprehensive metabolic panel | <1% | 414 | $121.84 |
| 83970 | <1% | 123 | $113.92 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 248 | $103.79 |
| 84403 | <1% | 136 | $92.66 | |
| 80061 | Lipid panel | <1% | 292 | $74.66 |
| 84402 | <1% | 118 | $71.35 | |
| 82627 | <1% | 123 | $62.12 | |
| 84270 | <1% | 119 | $60.31 | |
| 82670 | <1% | 108 | $55.88 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 408 | $51.14 |
| 83003 | <1% | 122 | $49.68 | |
| 84481 | <1% | 148 | $47.35 | |
| 82607 | <1% | 177 | $42.16 | |
| 84144 | <1% | 105 | $41.72 | |
| 82746 | <1% | 155 | $41.33 | |
| 82728 | <1% | 154 | $38.12 | |
| 83002 | <1% | 105 | $37.04 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 319 | $34.80 |
| 82785 | <1% | 542 | $26.28 | |
| 84439 | <1% | 142 | $25.16 | |
| 83550 | <1% | 135 | $23.70 | |
| 83735 | <1% | 136 | $18.83 | |
| 83540 | <1% | 153 | $18.09 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 281 | $13.28 |
| 81001 | <1% | 43 | $12.30 | |
| 84146 | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTSIKMAN, HERSHEL (OFFICER)